Cat. No. | Product Name / Activity |
---|---|
3066 | L 006235 |
Potent cathepsin K inhibitor | |
5085 | L 012 sodium salt |
Chemiluminescent ROS and RNS indicator | |
4013 | L 760735 |
High affinity NK1 antagonist | |
6251 | L Moses dihydrochloride |
High affinity and selective PCAF bromodomain inhibitor | |
2444 | (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 |
Potent and selective sst2 agonist | |
1382 | L-152,804 |
Potent, selective non-peptide NPY Y5 receptor antagonist | |
2514 | L-161,982 |
Selective EP4 receptor antagonist | |
1856 | L-165,041 |
Potent PPARδ agonist | |
2311 | L-168,049 |
Potent, orally active human glucagon receptor antagonist | |
2660 | L-364,373 |
KV7.1 channel activator, activates IKs | |
2767 | L-365,260 |
Selective CCK2 antagonist | |
2641 | L-368,899 hydrochloride |
Potent, non-peptide oxytocin receptor antagonist | |
2410 | L-371,257 |
Potent and selective oxytocin receptor antagonist | |
3086 | L-651,582 |
Non-selective Ca2+ channel blocker | |
1327 | L-655,708 |
Benzodiazepine inverse agonist; selective for α5-containing GABAA receptors | |
1949 | L-670,596 |
Potent, selective thromboxane A2/prostaglandin endoperoxide antagonist | |
2627 | L-685,458 |
Potent and selective γ-secretase inhibitor | |
0742 | L-689,560 |
Highly potent NMDA antagonist | |
0682 | L-690,488 |
Cell permeable prodrug of the IMPase inhibitor L-690,330 (Cat. No. 0681) | |
0681 | L-690,330 |
Inositol monophosphatase inhibitor | |
2261 | L-692,585 |
Potent, non-peptide ghrelin receptor agonist | |
0426 | L-693,403 maleate |
High affinity σ ligand | |
0781 | L-694,247 |
5-HT1D agonist | |
0705 | L-701,252 |
NMDA antagonist; acts at glycine site | |
0907 | L-701,324 |
NMDA antagonist; acts at glycine site | |
2640 | L-703,664 succinate |
Selective 5-HT1D agonist | |
0868 | L-732,138 |
Potent and selective NK1 antagonist | |
1145 | L-733,060 hydrochloride |
Potent NK1 antagonist | |
1004 | L-741,742 hydrochloride |
Highly selective D4 antagonist | |
1003 | L-741,626 |
High affinity D2 antagonist | |
1002 | L-745,870 trihydrochloride |
Highly selective D4 antagonist | |
2760 | L-748,337 |
Selective β3 antagonist | |
2197 | L-755,507 |
Very potent and selective β3 partial agonist | |
3342 | L-798,106 |
Potent and highly selective EP3 antagonist | |
1979 | L-803,087 trifluoroacetate |
Potent and selective sst4 agonist | |
1980 | L-817,818 |
Potent and selective sst5 agonist | |
3250 | L-838,417 |
GABAA partial agonist; displays subtype selectivity | |
6954 | L-Buthionine sulfoximine |
Irreversible γ-glutamylcysteine synthetase (γ-GCS) inhibitor; induces ferroptosis | |
6809 | L-DON |
Glutaminase inhibitor; also inhibits other glutamine-using enzymes and transporters | |
3788 | L-DOPA |
Dopamine precursor | |
5045 | L002 |
p300 inhibitor | |
3561 | L189 |
DNA ligase I, III and IV inhibitor | |
6146 | LAP |
Photocrosslinker for hydrogels | |
5592 | LCB 03-0110 dihydrochloride |
Potent c-SRC kinase inhibitor; also inhibits DDR2, BTK and Syk | |
7178 | LCL 161, phenol New |
Functionalized IAP ligand for PROTACs | |
6752 | LDC 000067 |
Potent and selective CDK9 inhibitor | |
5631 | LDN 193188 |
Inhibitor of phosphatidylcholine transfer protein (PC-TP) | |
6053 | LDN 193189 dihydrochloride |
Potent and selective ALK2 and ALK3 inhibitor; inhibits BMP4 signaling; promotes neural induction of hPSCs | |
4828 | LDN 209929 dihydrochloride |
Potent and selective haspin inhibitor | |
5082 | LDN 212320 |
Increases EAAT2 expression; neuroprotective | |
6151 | LDN 212854 |
Potent bone morphogenetic protein type I (ALK) inhibitor | |
6152 | LDN 214117 |
Potent and selective ALK2 inhibitor | |
4602 | LDN 27219 |
Transglutaminase 2 (TG2) inhibitor; reversible | |
3998 | LDN 57444 |
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor | |
7020 | LDV |
α4β1 (VLA-4) ligand | |
4577 | LDV FITC |
Fluorescent ligand for α4β1 (VLA-4) | |
2021 | LE 135 |
Selective RARβ antagonist | |
1674 | LE 300 |
Potent and selective D1 antagonist | |
5826 | LEI 101 hydrochloride |
Potent and selective CB2 partial agonist; orally biovailable | |
2985 | LEP (116-130) (mouse) |
Synthetic leptin peptide fragment | |
4421 | LF 11 |
Antibiotic; neutralizes LPS | |
1300 | LFM-A13 |
Potent, selective BTK inhibitor | |
5920 | LG 100268 |
Potent and selective RXR agonist; also activates RXR/PPARγ heterodimers | |
3831 | LG 100754 |
RXR:PPAR agonist | |
3508 | LG 101506 |
Selective RXR modulator | |
4896 | LH 846 |
Selective casein kinase 1δ inhibitor | |
4745 | LIMKi 3 |
Potent LIM kinase inhibitor; antitumor | |
6754 | LJI308 |
Potent pan-RSK inhibitor | |
5213 | LL 37 |
Antimicrobial peptide derivative of human cathelicidin | |
5365 | LLY 507 |
Potent SMYD2 inhibitor | |
5794 | LM 10 |
Selective tryptophan 2,3-dioxygenase (TDO) inhibitor | |
4607 | LM 22A4 |
Potent TrkB agonist | |
5046 | LM11A 31 dihydrochloride |
Nonpeptide p75NTR ligand; neuroprotective | |
6037 | LM22B 10 |
TrkB and TrkC agonist; brain penetrant | |
4830 | LMK 235 |
Selective HDAC4/HDAC5 inhibitor | |
6510 | LNT 1 |
Potent flap endonuclease 1 (FEN1) inhibitor; induces DNA damage response | |
5606 | LOC14 |
High affinity protein disulfide isomerase (PDI) modulator | |
2314 | LOE 908 hydrochloride |
Broad spectrum cation channel blocker; neuroprotective | |
6691 | LP 922056 |
Notum inhibitor; activates Wnt signaling | |
6229 | LP 922761 |
Potent AAK1 inhibitor; peripherally restricted | |
5496 | LP 99 |
Selective BRD7 and BRD9 inhibitor | |
4084 | LPYFD-NH2 |
Binds Aβ; protects from aggregation induced toxicity | |
3394 | LRGILS-NH2 |
Control peptide for SLIGRL-NH2 (Cat. No. 1468) | |
4273 | LRRK2-IN-1 |
Potent and selective LRRK2 inhibitor | |
5275 | LSN 2463359 |
Potent and selective positive allosteric modulator of mGlu5 receptors | |
5834 | LTURM 34 |
Potent DNA-PK inhibitor | |
5835 | LTURM 36 |
PI 3-kinase δ inhibitor | |
3562 | LU AA33810 |
Potent NPY Y5 receptor antagonist | |
4603 | LUF 5834 |
Potent adenosine A2A and A2B receptor partial agonist | |
4881 | LUF 6283 |
HCA2 (GPR109A) partial agonist | |
6322 | LW 6 New |
Malate dehydrogenase-2 (MDH2) inhibitor; also inhibits HIF-1α | |
7027 | LY 2033298 |
Selective positive allosteric modulator of M4 receptors; active in vivo; antipsychotic | |
4141 | LY 2087101 |
Allosteric potentiator of α7, α4β2 and α4β4 nAChRs | |
6964 | LY 2119620 |
Positive allosteric modulator of M2 and M4 receptors | |
1523 | LY 215840 |
5-HT2/5-HT7 antagonist | |
2452 | LY 2183240 |
Highly potent anandamide uptake inhibitor; also inhibits FAAH | |
1018 | LY 225910 |
Potent CCK2 antagonist | |
1286 | LY 231617 |
Antioxidant; neuroprotective in vitro and in vivo | |
1521 | LY 233053 |
Competitive NMDA antagonist | |
1019 | LY 235959 |
Competitive NMDA antagonist | |
3397 | LY 2365109 hydrochloride |
Potent and selective GlyT1 inhibitor | |
4969 | LY 2389575 hydrochloride |
Selective negative allosteric modulator of mGlu3 receptors | |
2208 | LY 255283 |
Selective, competitive BLT2 receptor antagonist | |
6454 | LY 2603618 |
Potent and selective Chk1 inhibitor | |
4081 | LY 266097 hydrochloride |
Selective 5-HT2B antagonist | |
3077 | LY 272015 hydrochloride |
High affinity 5-HT2B antagonist; orally active | |
1524 | LY 288513 |
Selective CCK2 antagonist | |
7081 | LY 2886721 Hydrochloride |
Potent and selective β-secretase (BACE) inhibitor | |
1130 | LY 294002 hydrochloride |
Prototypical PI 3-kinase inhibitor; also inhibits other kinases | |
5984 | LY 2955303 |
High affinity and selective RARγ antagonist | |
6854 | LY 3009120 |
Potent pan-Raf kinase inhibitor | |
2418 | LY 303511 |
Negative control of LY 294002 (Cat. No. 1130) | |
3078 | LY 310762 hydrochloride |
Selective 5-HT1D antagonist | |
2387 | LY 320135 |
Selective CB1 inverse agonist | |
4738 | LY 333531 hydrochloride |
Protein kinase C inhibitor; selective for β isozymes | |
3079 | LY 334370 hydrochloride |
Selective 5-HT1F agonist | |
1209 | LY 341495 |
Highly potent and selective group II mGlu antagonist | |
4062 | LY 341495 disodium salt |
Potent and selective group II mGlu antagonist; disodium salt of LY 341495 (Cat. No. 1209) | |
2451 | LY 344864 hydrochloride |
Potent and selective 5-HT1F agonist | |
3246 | LY 354740 |
Potent and highly selective group II mGlu agonist | |
2718 | LY 364947 |
Selective inhibitor of TGF-βRI | |
1237 | LY 367385 |
Selective mGlu1a antagonist | |
2453 | LY 379268 |
Highly selective group II mGlu agonist | |
5064 | LY 379268 disodium salt |
Selective group II mGlu agonist; sodium salt of LY 379268 (Cat. No. 2453) | |
3350 | LY 393558 |
Dual 5-HT1B and 5-HT1D antagonist; also 5-HT re-uptake inhibitor | |
3272 | (±)-LY 395756 |
Mixed mGlu2 agonist/ mGlu3 antagonist | |
5297 | LY 404187 |
Selective positive allosteric modulator of AMPA receptors | |
6559 | LY 450139 |
γ-secretase pseudo-inhibitor | |
2390 | LY 456236 hydrochloride |
Selective mGlu1 antagonist | |
3283 | LY 487379 hydrochloride |
Selective positive allosteric modulator of mGlu2 receptors | |
4060 | LY 78335 |
Phenylethanolamine-N-methyltransferase inhibitor | |
2267 | Lactacystin |
Cell-permeable, potent and selective proteasome inhibitor | |
6098 | Lalistat 1 |
Potent and selective LAL inhibitor | |
6099 | Lalistat 2 |
Selective LAL inhibitor | |
1611 | Lamotrigine |
Inhibits glutamate release. Anticonvulsant | |
2289 | Lamotrigine isethionate |
Inhibits glutamate release. Water-soluble salt of lamotrigine (Cat. No. 1611) | |
2582 | Lansoprazole |
H+,K+-ATPase inhibitor | |
1293 | β-Lapachone |
DNA topoisomerase I inhibitor | |
6811 | Lapatinib |
Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor | |
4757 | Latanoprost |
FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors | |
3973 | Latrunculin A |
Inhibitor of actin assembly and polymerization | |
3974 | Latrunculin B |
Inhibitor of actin polymerization | |
4007 | Laulimalide |
Microtubule stabilzing agent | |
0548 | (±)-Lauroylcarnitine chloride |
Intermediate in lipid metabolism | |
4422 | Lauryl-LF 11 |
Analog of LF 11 (Cat. No. 4421); antibiotic | |
1331 | Lavendustin A |
EGFR, p60c-src inhibitor | |
2460 | Lazabemide hydrochloride |
Selective MAO-B inhibitor | |
2139 | Leelamine hydrochloride |
CB1 agonist | |
5571 | Lei-Dab 7 |
High affinity and selective KCa2.2 (SK) blocker | |
6305 | Lenalidomide |
Cereblon binder; induces ubiquitination and degradation of CK1α by E3 ubiquitin ligase | |
7075 | Lenalidomide 4'-PEG1-amine New |
Cereblon ligand with PEG linker and terminal amine for onward chemistry | |
7093 | Lenalidomide 4'-PEG2-amine New |
Cereblon ligand with PEG linker and terminal amine for onward chemistry | |
7076 | Lenalidomide 4'-PEG3-amine New |
Cereblon ligand with PEG linker and terminal amine for onward chemistry | |
1987 | Leptomycin B |
Inhibits nuclear export of proteins; antitumor | |
2959 | Lercanidipine hydrochloride |
CaV1.x blocker | |
3395 | Lestaurtinib |
JAK2, FLT3 and TrkA inhibitor; also inhibits AurA and AurB | |
4382 | Letrozole |
Potent, reversible non-steroidal aromatase inhibitor | |
4921 | Leukadherin 1 |
Allosteric activator of CD11b/CD18 | |
2307 | Leukotriene B4 |
BLT1/BLT2 receptor agonist and potent chemotactic factor | |
1167 | Leupeptin hemisulfate |
Inhibits trypsin-like/cysteine proteases | |
2873 | Leuprolide |
GnRH receptor agonist | |
1378 | Levcromakalim |
Kir6 (KATP) channel opener; active enantiomer of cromakalim (Cat. No. 1377) | |
2839 | Levetiracetam |
Binds SV2A; antiepileptic | |
4833 | Levonorgestrel |
Synthetic progesterone analog | |
2705 | Liarozole dihydrochloride |
Blocks retinoic acid metabolism | |
3865 | Licarbazepine |
Active metabolite of oxcarbazepine (Cat. No. 3864) | |
3057 | Lidocaine |
Na+ channel blocker | |
6068 | Lin28 1632 |
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor | |
3765 | Linezolid |
Antibiotic; inhibits protein synthesis in gram-positive bacteria | |
1461 | Linomide |
Immunomodulator with antiangiogenic properties | |
1999 | Linopirdine dihydrochloride |
KV7 (KCNQ) channel blocker | |
7045 | (±)-α-Lipoamide |
Phase-separated condensate modifier; orally bioavailable | |
7044 | (±)-α-Lipoic acid |
Liquid-liquid phase separated condensate modifier; reduces stress granule formation | |
6113 | Liproxstatin-1 hydrochloride |
Potent ferroptosis inhibitor | |
6517 | Liraglutide |
Highly potent, long-acting GLP-1 receptor agonist | |
4052 | Lisuride maleate |
Dopamine agonist; antiparkinson's agent | |
4740 | Lithium carbonate |
Mood stabilizer; inhibits GSK-3 in vivo | |
1916 | Litorin |
Amphibian bombesin-like peptide | |
1077 | (-)-Lobeline hydrochloride |
Nicotinic partial agonist | |
2690 | Locustatachykinin I |
Insect tachykinin-related peptide (TRP) | |
2545 | Lofepramine |
5-HT and NA reuptake inhibitor (SNRI) | |
4359 | Lomeguatrib |
MGMT inhibitor | |
6265 | Lonafarnib |
Potent farnesyltransferase inhibitor | |
1646 | Lonidamine |
Mitochondrial hexokinase inhibitor | |
0840 | Loperamide hydrochloride |
Peripherally acting μ agonist; Ca2+ channel blocker | |
7052 | Lopinavir |
Highly potent and selective HIV-1 protease inhibitor | |
1944 | Loratidine |
Peripheral H1 antagonist; antiallergic agent | |
1295 | Loreclezole hydrochloride |
Subtype-selective GABAA modulator | |
3798 | Losartan potassium |
Selective, non-peptide AT1 antagonist | |
1530 | Lovastatin |
Potent HMG-CoA reductase inhibitor | |
3036 | Loxiglumide |
CCK1 antagonist; active in vivo | |
5427 | D-Luciferin sodium salt |
Firefly luciferase substrate; cell permeable. | |
2874 | Luteolin |
Anti-inflammatory, antioxidant and free radical scavenger | |
0877 | Luzindole |
Competitive melatonin MT1/MT2 antagonist | |
2265 | Lyn peptide inhibitor |
Inhibits Lyn-dependent activities of IL-5 receptor; cell-permeable | |
5103 | Lys-CoA |
Selective p300 inhibitor | |
3611 | Lys-γ3-MSH |
Pro-opiomelanocortin (POMC) derived peptide |